Protara Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Protara announced Q2 2026 financial results with cash/investments of $161.9M as of June 30, 2026, sufficient to fund operations into 2028. The company expects to complete enrollment of the BCG-Unresponsive ADVANCED-2 trial cohort in Q4 2026 and redesigned ADVANCED-3 as a multi-cohort exploratory trial. TARA-002 in lymphatic malformations showed 83% clinical success (10/12 participants) with BLA submission planned for 2H 2027; THRIVE-3 interim results expected Q4 2026. Q2 net loss was $21.7M ($0.36/share) vs. $15.0M prior year, with R&D expenses increasing to $17.0M from $10.8M.
Why this rating
Operational progress on trials and adequate cash runway are routine for clinical-stage biotech; $21.7M quarterly burn is 19% of $112M market cap but expected. No major deal, regulatory approval, or capital event occurred.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.